Company intelligence / Profile preview

DTPx Therapeutics

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Early-stage oncology biotech developing a novel immunotherapy/cell-based approach that targets hibernating cancer cells to prevent relapse in colorectal cancer; currently at preclinical research stage with no publicly reported clinical trial results.[1][3][4]

Therapeutic areas: Oncology
Modalities: Cell therapy
Industry: Biotech

Partnerships

FACITOntario Institute for Cancer Research (via FACIT commercialization ecosystem)

Beyond the preview

Go deeper on DTPx Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DTPx Therapeutics.

Explore the full profile